Poly Medicure Ltd (POLYMED) Q2FY26 Concall Summary - Sep-2025 Qtr
Performance Overview
- The company demonstrated resilient performance, marked by strong double-digit growth in its domestic business, which grew 17-18% YoY, increasing its contribution to 32% of total revenue.
- Despite a challenging international environment, particularly in Europe, the company maintained healthy operating EBITDA margins at the higher end of its guidance, supported by an improvement in gross margins.
- Strategic expansion into the orthopedic trauma segment was a key highlight, achieved through the acquisition of Italy-based CDFE Group, which is expected to add approximately INR 280 crores in annual revenue along with the Pender Care Group acquisition.
- The company is aggressively investing in future growth, with a planned capital expenditure of over INR 250 crores for FY26, directed towards setting up new facilities and expanding existing capacities.
- While international business faced headwinds, there are signs of recovery with a 9.1% sequential growth in Q2, driven by improving customer sentiment and focused efforts in Rest of the World (ROW) markets.
Financial Metrics
Log in to Stocksigma to read the Financial Metrics section of this summary.
Operating Performance / Business Segments
Log in to Stocksigma to read the Operating Performance / Business Segments section of this summary.
Key Discussions & Insights
Log in to Stocksigma to read the Key Discussions & Insights section of this summary.
Outlook and Guidance
Log in to Stocksigma to read the Outlook and Guidance section of this summary.
Challenges / Concerns
Log in to Stocksigma to read the Challenges / Concerns section of this summary.
Industry / Competitive Landscape
Log in to Stocksigma to read the Industry / Competitive Landscape section of this summary.
Overall Summary
Log in to Stocksigma to read the Overall Summary section of this summary.